← The SEC Ephemeris: the whole map
Merck & Co., Inc. Suvorexant
In the graph: all 10 documents (261 pages).
- Application
- NDA 204569
- Ticker
- MRK
- Product
- Suvorexant
- Disease area
- Not yet classified
- Response path
- Not yet classified
- Complete Response Letters
- June 28, 2013
From FDA letters and SEC filings. Not investment or medical advice.